Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

导出 OA

翻译打印收藏纠错

作者： Paavo O,Pietarinen ^[1] ; Christopher A,Eide ^[2] ; Pilar,Ayuda-Durán ^[3] ; Swapnil,Potdar ^[4] ; Heikki,Kuusanmäki ^[5] ; Emma I,Andersson ^[5] ; John P,Mpindi ^[1] ; Tea,Pemovska ^[5] ; Mika,Kontro ^[5] ; Caroline A,Heckman ^[6] ; Olli,Kallioniemi ^[1] ; Krister,Wennerberg ^[5] ; Henrik,Hjorth-Hansen ^[5] ; Brian J,Druker ^[5] ; Jorrit M,Enserink ^[7] ; Jeffrey W,Tyner ^[2] ; Satu,Mustjoki ^[3] ; Kimmo,Porkka ^[4]

作者单位： Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. ^[1] Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. ^[2] Howard Hughes Medical Institute, Portland, OR, USA. ^[3] Oslo University Hospital, University of Oslo, Oslo, Norway. ^[4] Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ^[5] Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria. ^[6] Department of Hematology, St Olavs Hospital, Trondheim, Norway and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. ^[7] Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA. ^[8] Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. ^[9]

关键词 CD34 chronic myeloid leukemia ex vivo high-throughput drug screening tyrosine kinase inhibitors